Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera
Eli Lilly is leaving nothing to chance when it comes to making the most of its fast-growing diabetes therapy Mounjaro – it is investing another $450million at a facility in North Carolina t
Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established ri